BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BerGenBio AS Secures Additional $6 Million as First in Class AXL Kinase Inhibitor BGB324 Approaches Clinic


5/31/2013 10:24:23 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Bergen, May 29, 2013, BerGenBio, an emerging oncologybiopharma, today announced that it has secured an additional $6 million from existing investors , Investinor, Sarsia Seed, Birk Venture, RO Invest and Meteva, as lead candidate BGB324 prepares to enter Phase I trials in Europe. BGB324 is an oral, selective first in class AXL receptor tyrosine kinase inhibitor that targets tumour epithelial-mesenchymal transition (EMT) and is expected to be useful in the treatment of drug-resistant solid and haematological malignancies, including lung, pancreatic, breast cancer and myeloid leukemia.

Richard Godfrey, BerGenBio’s CEO said the additional funding would be used to support ongoing R&D activities, including the early clinical evaluation of BGB324: “The therapeutic potential of AXL inhibition in general, and BGB324 in particular, attracted a great deal of interest recently at AACR and is the subject of several posters at ASCO. Our preclinical studies show that inhibiting AXL activity with BGB324 in combination with standard of care cytotoxics and targeted therapies is veryeffective in preventing and reversing acquired resistance such as Erlotinib-resistant NSCLC. Furthermore, used as a single agent BGB324 causes significant tumourregression in models of AML. We now look forward to taking BGB324 into the clinic and potentially providing an important new tool in the fight against drug-resistant cancer.”



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES